Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupDermatologic OncologyT-Cell and NK-Cell NeoplasmsDiseaseNHL, T-Cell Type, Cutaneous, UnspecifiedNHL, T-Cell Type, Cutaneous Primary, CD30-PositiveNHL, T-Cell Type, Mycosis FungoidesNHL, T-Cell Type, Peripheral, UnspecifiedNHL, T-Cell Type, Sézary SyndromeSubgroupCD30+ICD10C84.0C84.1C84.4C84.8C86.6MeSHLymphoma, T-Cell, CutaneousMycosis FungoidesSezary SyndromeSequenceMAVORIC: MOGA1, CTCL, C1 (PID1397) -|- C2-12 (PID1398)ChemotherapyChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineMogamulizumabChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineMogamulizumabChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineMogamulizumabChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineMogamulizumabNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolPyridoxineSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolPyridoxineSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolPyridoxineSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolPyridoxineNo. Substances234Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRelapse therapySecond lineseveral possibleThird line Therapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaDiarrheaEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHand-Foot SyndromeHepatotoxicityHypertensionIncrease AminotransferasesInfusion ReactionLeukopeniaMucositisNauseaNeuropathyNeutropeniaPneumoniaPruritusPyrexiaSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorDuvic MKim YHPrince HMQuereux GZinzani PLDiseasefortgeschrittenes, kutanes T-Zell-Lymphomkutanes T-Zell-Lymphom, CD30+, mindestens eine Vortherapie, ECOG 0-2Peripheres T-Zell Lymphom oder Mykosis fungoides, mindestens 2 Vortherapienrefraktäres oder rezidivierendes kutanes T-Zell-Lymphom, 2 oder mehr Vorbehandlungen, ECOG 0-2refraktäres oder rezidivierendes kutanes T-Zell-Lymphom, eine oder mehr Vorbehandlungen, ECOG 0-1OriginDepartment of Dermatology, The University of Texas M. D. Anderson Cancer Center, HoustonDepartments of Dermatology, Centre Hospitalier Universitaire, Nantes, FranceDivision of Cancer Medicine, Peter MacCallum Cancer Centre, The University of Melbourne, ALCANZAInstitute of Hematology and Medical Oncology, University of Bologna, Bologna, ItalyStanford University, Stanford, CA, USA, MAVORICProtocols in Revision 6 protocols foundProtocols under revision.Brentuximab Vedotin 1.8, cutaneous T-cell lymphoma (PID1389 V1.0)Gemcitabine 1000, cutaneous T-cell lymphoma (PID1388 V1.0)Gemcitabine 1200, T-cell Lymphoma (PID1924 V1.0)Mogamulizumab 1, cutaneous T-cell lymphoma, cycle 1 (PID1397 V1.0)Mogamulizumab 1, cutaneous T-cell lymphoma, cycle 2-12 (PID1398 V1.0)Pegylated Doxorubicin Liposomal 40, cutaneous T-cell lymphoma (PID1387 V1.0)
